Molecular and biochemical carrier screening in our family identified three more carriers, two with
the c.1305CNT and one with c.78GNA (Fig. 1). Carriers with the c.1305CNT mutation had reduced
β-hexosaminidase A levels in the plasma or leucocytes or both, thus supporting the pathogenic role of this
mutation.